课题基金 / 基金详情

CLC-5 Inactivation and Hypercalciuria in Dent's Disease

CLC-5 Inactivation and Hypercalciuria in Dent's Disease
Dent 病中的 CLC-5 失活和高钙尿症
批准号:
6698782
负责人:
STEVEN J SCHEINMAN
金额:
$15.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-02-01 至 2008-01-31

项目摘要

项目成果

STEVEN J SCHEINMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hypercalciuria is the most common risk factor for calcium oxalate stone disease and often has an hereditary component. The first inherited hypercalciuric syndrome for which the gene was identified was X-linked nephrolithiasis (Dent's disease), which is caused by inactivating mutations in the CLCN5 gene encoding the voltage-gated chloride channel C1C-5, expressed in subapical endosomes of renal proximal tubular cells. However, other than low molecular-weight (LMW) proteinuria, we do not know how this explains other features of the disease such as hypercalciuria, which is the major risk factor for calcium oxalate stone formation in patients with Dent' s disease, nor why proximal tubular production of 1,25(OH)2 vitamin D is excessive. Our hypothesis is that defective function of C1C-5 in endosomes leads to altered membrane and protein trafficking that perturbs the integrity of the cellular vesicular transport network. This could explain altered function of apical Na-dependent transport processes such as reabsorption of phosphate. Further, since 1a-hydroxylation of 25(OH)2 D occurs in proximal tubular cells, it is possible that dysregulation of the 1a-hydroxylase is a secondary consequence of altered membrane trafficking. We will address this hypothesis in cultured HK-2 human proximal tubular cells in which we have used a ribozyme to reduce C1C-5 expression. In preliminary studies we have demonstrated changes in membrane trafficking and solute transport in these knockdown cells. Using this model our specific aims are to determine the consequences of reduced C1C-5 expression on: (1) membrane trafficking, (2) solute transport (particularly Na-dependent phosphate transport), and (3) 1a-hydroxylation of vitamin D. We expect that these pilot studies will offer significant insights into the mechanisms of calcium oxalate stone formation in Dent's disease and provide the foundation for further studies using this in vitro cell culture model to address mechanisms of hypercalciuria and renal failure.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
CLC-5 Inactivation and Hypercalciuria in Dent's Disease
  • 批准号:
    6559378
  • 项目类别:
  • 资助金额:
    $15.2万
  • 财政年份:
    2003
  • 负责人:
    STEVEN J SCHEINMAN
  • 依托单位:
GENETIC MAPPING IN THE HYPERCALCIURIC STONE-FORMING RAT
  • 批准号:
    6517753
  • 项目类别:
  • 资助金额:
    $30.2万
  • 财政年份:
    2000
  • 负责人:
    STEVEN J SCHEINMAN
  • 依托单位:
GENETIC MAPPING IN THE HYPERCALCIURIC STONE-FORMING RAT
  • 批准号:
    6664323
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2000
  • 负责人:
    STEVEN J SCHEINMAN
  • 依托单位:
GENETIC MAPPING IN THE HYPERCALCIURIC STONE-FORMING RAT
  • 批准号:
    6088884
  • 项目类别:
  • 资助金额:
    $31.48万
  • 财政年份:
    2000
  • 负责人:
    STEVEN J SCHEINMAN
  • 依托单位:
国内基金
海外基金
Calcium/NFAT/GLUT3通路调控糖酵解代谢在CAR-T细胞耗竭中的作用和机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    张明明
  • 依托单位:
钙信号负向调节因子IRBIT抑制肝癌细胞恶性生物学行为的分子机制研究
  • 批准号:
    31960151
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    40.0万元
  • 批准年份:
    2019
  • 负责人:
    徐靖宇
  • 依托单位:
基于钙信号特征机制的肿瘤转移调控研究
  • 批准号:
    31970729
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    魏朝亮
  • 依托单位:
一种拟南芥IP3结合蛋白作用机制及功能研究
  • 批准号:
    31970723
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2019
  • 负责人:
    韩生成
  • 依托单位: